UNSPSC 51173205: Benzocaine/docusate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS300. This VA Drug Class (RS300) classifies this compound as belonging to the group LAXATIVES, RECTAL.

UNSPSC 51173205 Benzocaine/docusate is a Commodity code naming a single pharmaceutical product line, but recent state and local solicitations tagged under this code encompass a much broader scope: drug testing services, pharmaceutical supply chain management, and generic medication procurement across multiple wholesaler and distribution networks. State and local governments are using this code to solicit specimen collection and immunoassay screening, therapeutic pharmacy initiatives involving direct-to-manufacturer contracting, and generic multi-source pharmaceutical supply through cooperative purchasing vehicles. Issuing bodies include county corrections departments, state health and human services agencies, and multi-state cooperative purchasing alliances. The work ranges from operational drug-testing services with lab certification and result reporting requirements to upstream pharmaceutical sourcing and pricing negotiations with manufacturers and authorized wholesalers.

Activity appears concentrated in Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 over two years plus three optional one-year renewals, requiring SAMHSA, Texas DPS, or CAP lab certification and per-test pricing across five-panel, six-panel, and ancillary testing formats. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program without formal award timelines or budget disclosure. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 with proposals due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026, and performance penalties of $200 to $1,500 per violation for late reporting or missed onboarding.